Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results

Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results

Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the long-term efficacy of this therapy. The aim of our study was to evaluate the efficacy and long-term result...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical drug investigation 2005-10, Vol.25 (10), p.661
Hauptverfasser: Bostanci, Seher, Kocyigit, Pelin, Alp, Aysegul, Erdem, Cengizhan, Gurgey, Erbak
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 10
container_start_page 661
container_title Clinical drug investigation
container_volume 25
creator Bostanci, Seher
Kocyigit, Pelin
Alp, Aysegul
Erdem, Cengizhan
Gurgey, Erbak
description Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the long-term efficacy of this therapy. The aim of our study was to evaluate the efficacy and long-term results of interferon α-2a (IFNα-2a) in the treatment of basal cell carcinoma. Methods: Twenty dermatopathologically proven basal cell carcinoma lesions were treated with Intralesional IFNα-2a injections three times weekly for 3 weeks. The dose per injection was 1.5 x [10.sup.6] IU if the lesion was
doi_str_mv 10.2165/00044011-200525100-00005
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A199858424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A199858424</galeid><sourcerecordid>A199858424</sourcerecordid><originalsourceid>FETCH-LOGICAL-g137t-59319bee9412e3a8a3f7e3df9ae8b12235fb2d4ca88c55b816bebb0778963ffc3</originalsourceid><addsrcrecordid>eNptj0tOAzEMhmcBEqVwh0isU_KYzGTEqqp4SUhsyrpyMk4byCRoJqUX4SJchDMRBAsWKJIt__7826kqwtlC8EZdMsbqmnFOBWNKKM4YLRJTR9WM81ZSoRp5Up1O0zNjvOGNmFXv6xEhDxgzSY4YmCAQi6EEGK2PaQASkoWMPfGR5B2SHUJPIPYkon0hI259iuTg864AeYSAUxGKS6lwdDiW7ucHFXBF8A3CHvI3X3aFFLe0IANxKYR0oPvX4jbtQ57OqmMHYcLz3zyvnm6u16s7-vB4e79aPtAtl22mqpO8M4hdzQVK0CBdi7J3HaA2XAipnBF9bUFrq5TRvDFoDGtb3TXSOSvn1cWP77acvfHRpfIBO_jJbpa867TStagLtfiHKq_HwdsU0fmi_xn4AsbYepY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results</title><source>SpringerLink Journals - AutoHoldings</source><creator>Bostanci, Seher ; Kocyigit, Pelin ; Alp, Aysegul ; Erdem, Cengizhan ; Gurgey, Erbak</creator><creatorcontrib>Bostanci, Seher ; Kocyigit, Pelin ; Alp, Aysegul ; Erdem, Cengizhan ; Gurgey, Erbak</creatorcontrib><description>Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the long-term efficacy of this therapy. The aim of our study was to evaluate the efficacy and long-term results of interferon α-2a (IFNα-2a) in the treatment of basal cell carcinoma. Methods: Twenty dermatopathologically proven basal cell carcinoma lesions were treated with Intralesional IFNα-2a injections three times weekly for 3 weeks. The dose per injection was 1.5 x [10.sup.6] IU if the lesion was &lt;2cm in diameter and 3.0 x [10.sup.6] IU if it was ≥2cm. Eight weeks after the last injection, the lesion sites were rebiopsied and all cases were reevaluated both clinically and dermatopathologically. Patients with complete cure were followed up for 7 years to determine the long-term results. Results: Eleven lesions (55%) showed complete clinical and dermatopathological remission, six lesions (30%) showed partial remission, and two lesions (10%) showed no response. One lesion (5%) increased in size during the treatment. No serious adverse effects were observed. During the follow-up period there was only one recurrence, at the fifth year. Conclusion: Treatment with Intralesional IFNα-2a was shown to be an effective therapeutic option for basal cell carcinoma, with low recurrence rates in long-term follow-up.</description><identifier>ISSN: 1173-2563</identifier><identifier>DOI: 10.2165/00044011-200525100-00005</identifier><language>eng</language><publisher>Wolters Kluwer Health, Inc</publisher><ispartof>Clinical drug investigation, 2005-10, Vol.25 (10), p.661</ispartof><rights>COPYRIGHT 2005 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Bostanci, Seher</creatorcontrib><creatorcontrib>Kocyigit, Pelin</creatorcontrib><creatorcontrib>Alp, Aysegul</creatorcontrib><creatorcontrib>Erdem, Cengizhan</creatorcontrib><creatorcontrib>Gurgey, Erbak</creatorcontrib><title>Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results</title><title>Clinical drug investigation</title><description>Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the long-term efficacy of this therapy. The aim of our study was to evaluate the efficacy and long-term results of interferon α-2a (IFNα-2a) in the treatment of basal cell carcinoma. Methods: Twenty dermatopathologically proven basal cell carcinoma lesions were treated with Intralesional IFNα-2a injections three times weekly for 3 weeks. The dose per injection was 1.5 x [10.sup.6] IU if the lesion was &lt;2cm in diameter and 3.0 x [10.sup.6] IU if it was ≥2cm. Eight weeks after the last injection, the lesion sites were rebiopsied and all cases were reevaluated both clinically and dermatopathologically. Patients with complete cure were followed up for 7 years to determine the long-term results. Results: Eleven lesions (55%) showed complete clinical and dermatopathological remission, six lesions (30%) showed partial remission, and two lesions (10%) showed no response. One lesion (5%) increased in size during the treatment. No serious adverse effects were observed. During the follow-up period there was only one recurrence, at the fifth year. Conclusion: Treatment with Intralesional IFNα-2a was shown to be an effective therapeutic option for basal cell carcinoma, with low recurrence rates in long-term follow-up.</description><issn>1173-2563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptj0tOAzEMhmcBEqVwh0isU_KYzGTEqqp4SUhsyrpyMk4byCRoJqUX4SJchDMRBAsWKJIt__7826kqwtlC8EZdMsbqmnFOBWNKKM4YLRJTR9WM81ZSoRp5Up1O0zNjvOGNmFXv6xEhDxgzSY4YmCAQi6EEGK2PaQASkoWMPfGR5B2SHUJPIPYkon0hI259iuTg864AeYSAUxGKS6lwdDiW7ucHFXBF8A3CHvI3X3aFFLe0IANxKYR0oPvX4jbtQ57OqmMHYcLz3zyvnm6u16s7-vB4e79aPtAtl22mqpO8M4hdzQVK0CBdi7J3HaA2XAipnBF9bUFrq5TRvDFoDGtb3TXSOSvn1cWP77acvfHRpfIBO_jJbpa867TStagLtfiHKq_HwdsU0fmi_xn4AsbYepY</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Bostanci, Seher</creator><creator>Kocyigit, Pelin</creator><creator>Alp, Aysegul</creator><creator>Erdem, Cengizhan</creator><creator>Gurgey, Erbak</creator><general>Wolters Kluwer Health, Inc</general><scope/></search><sort><creationdate>20051001</creationdate><title>Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results</title><author>Bostanci, Seher ; Kocyigit, Pelin ; Alp, Aysegul ; Erdem, Cengizhan ; Gurgey, Erbak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g137t-59319bee9412e3a8a3f7e3df9ae8b12235fb2d4ca88c55b816bebb0778963ffc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bostanci, Seher</creatorcontrib><creatorcontrib>Kocyigit, Pelin</creatorcontrib><creatorcontrib>Alp, Aysegul</creatorcontrib><creatorcontrib>Erdem, Cengizhan</creatorcontrib><creatorcontrib>Gurgey, Erbak</creatorcontrib><jtitle>Clinical drug investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bostanci, Seher</au><au>Kocyigit, Pelin</au><au>Alp, Aysegul</au><au>Erdem, Cengizhan</au><au>Gurgey, Erbak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results</atitle><jtitle>Clinical drug investigation</jtitle><date>2005-10-01</date><risdate>2005</risdate><volume>25</volume><issue>10</issue><spage>661</spage><pages>661-</pages><issn>1173-2563</issn><abstract>Objective: Intralesional injections of interferon have been reported to provide successful results in the treatment of basal cell carcinoma. However, there are only a few reports describing the long-term efficacy of this therapy. The aim of our study was to evaluate the efficacy and long-term results of interferon α-2a (IFNα-2a) in the treatment of basal cell carcinoma. Methods: Twenty dermatopathologically proven basal cell carcinoma lesions were treated with Intralesional IFNα-2a injections three times weekly for 3 weeks. The dose per injection was 1.5 x [10.sup.6] IU if the lesion was &lt;2cm in diameter and 3.0 x [10.sup.6] IU if it was ≥2cm. Eight weeks after the last injection, the lesion sites were rebiopsied and all cases were reevaluated both clinically and dermatopathologically. Patients with complete cure were followed up for 7 years to determine the long-term results. Results: Eleven lesions (55%) showed complete clinical and dermatopathological remission, six lesions (30%) showed partial remission, and two lesions (10%) showed no response. One lesion (5%) increased in size during the treatment. No serious adverse effects were observed. During the follow-up period there was only one recurrence, at the fifth year. Conclusion: Treatment with Intralesional IFNα-2a was shown to be an effective therapeutic option for basal cell carcinoma, with low recurrence rates in long-term follow-up.</abstract><pub>Wolters Kluwer Health, Inc</pub><doi>10.2165/00044011-200525100-00005</doi></addata></record>
fulltext fulltext
identifier ISSN: 1173-2563
ispartof Clinical drug investigation, 2005-10, Vol.25 (10), p.661
issn 1173-2563
language eng
recordid cdi_gale_infotracmisc_A199858424
source SpringerLink Journals - AutoHoldings
title Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α-2a; evaluation of long-term follow-up results
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T07%3A45%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20basal%20cell%20carcinoma%20located%20in%20the%20head%20and%20neck%20region%20with%20intralesional%20interferon%20%CE%B1-2a;%20evaluation%20of%20long-term%20follow-up%20results&rft.jtitle=Clinical%20drug%20investigation&rft.au=Bostanci,%20Seher&rft.date=2005-10-01&rft.volume=25&rft.issue=10&rft.spage=661&rft.pages=661-&rft.issn=1173-2563&rft_id=info:doi/10.2165/00044011-200525100-00005&rft_dat=%3Cgale%3EA199858424%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A199858424&rfr_iscdi=true